Home500257 • BOM
Lupin Ltd
add
In the news
LUPIN
1.19%
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
(INR) | Mar 2025info | Y/Y change |
---|---|---|
Revenue | 56.67B | 14.24% |
Operating expense | 29.68B | 34.53% |
Net income | 7.73B | 114.93% |
Net profit margin | 13.63 | 88.00% |
Earnings per share | 16.87 | 114.63% |
EBITDA | 13.05B | 41.04% |
Effective tax rate | 12.67% | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
(INR) | Mar 2025info | Y/Y change |
---|---|---|
Cash and short-term investments | 42.01B | 106.51% |
Total assets | 292.05B | 21.70% |
Total liabilities | 119.11B | 23.76% |
Total equity | 172.94B | — |
Shares outstanding | 456.30M | — |
Price to book | 5.12 | — |
Return on assets | — | — |
Return on capital | 12.08% | — |
Cash Flow
Net Change in Cash
Net change in cash
(INR) | Mar 2025info | Y/Y change |
---|---|---|
Net income | 7.73B | 114.93% |
Cash from operations | — | — |
Cash from investing | — | — |
Cash from financing | — | — |
Net change in cash | — | — |
Free cash flow | — | — |
Previous close
₹1,929.75
Day range
₹1,938.70 - ₹1,961.10
Year range
₹1,767.20 - ₹2,403.45
Market cap
891.97B INR
Avg Volume
33.80K
P/E ratio
27.26
Dividend yield
0.61%
Primary exchange
NSE
About
Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is primarily a manufacturer of generic drugs, covering therapeutic areas such as paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis. Wikipedia
Founded
1968
Headquarters
Website
Employees
19,210